Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

By Loth Hammar

January 27, 2009 12:00 AM

The deal grants the Chinese

pharmaceutical company Novamed the exclusive rights to submit a registration application for the Chinese market för Abstral, a product developed by Orexo, to treat break-through pain in cancer patients. Novamed will also conduct the clinical study program required for a Chinese market registration. After registration Novamed will market and sell the product in China.

To Orexo the deal is worth

up to MUSD 4.75, partly as an initial fee and partly as milestone payments. Orexo is also granted a non-disclosed part of the future sales.

The deal is a first step into one of the fastest growing pharmaceutical markets of the world.

"Novamed have an experienced

marketing- and sales organization with a sales force of 400 and a broad product portfolio for treatment of cancer. This makes the company an ideal partner for us in China,” states Torbjörn Bjerke, CEO of Orexo.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.